Replies to post #44751 on Biotech Values

[DewDiligence]

>And off-label use in AMD but they won't be mentioning that!<

According to the CC, off-label Avastin in AMD is slightly down quarter over quarter. Lucentis market share is up slightly to 55%, but Lucentis sales are slightly down because the initial bolus of untreated patients has been exhausted.